Source:http://linkedlifedata.com/resource/pubmed/id/18451546
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0000854,
umls-concept:C0001688,
umls-concept:C0016360,
umls-concept:C0023884,
umls-concept:C0034693,
umls-concept:C0185125,
umls-concept:C0205148,
umls-concept:C0205373,
umls-concept:C0392756,
umls-concept:C0879626,
umls-concept:C1373200,
umls-concept:C1521970,
umls-concept:C1546465,
umls-concept:C1704711,
umls-concept:C1705175,
umls-concept:C1705176,
umls-concept:C1705177,
umls-concept:C1705178,
umls-concept:C1882348
|
pubmed:issue |
5
|
pubmed:dateCreated |
2008-5-2
|
pubmed:abstractText |
The present study was undertaken to elucidate the absorption and distribution characteristics of 5-fluorouracil (5-FU) after its application to the liver surface in rats to examine the possibility of reducing the systemic side effects of this agent. 5-FU was applied to the surface of the liver by employing a cylindrical diffusion cell. Approximately 69% of the dose was absorbed in 360 min. The time course of the change in the amount of 5-FU remaining in the diffusion cell obeyed first-order kinetics. Also, a linear relationship was observed between the apparent permeability coefficient, P app, and the reciprocal of the square root of the molecular weight of several compounds including 5-FU. The estimated P app value of 5-FU was in good agreement with the experimental value. The plasma concentration of 5-FU was low (<1.2 microg/ml) until 360 min after the application. Following i.v. administration, 5-FU was rapidly eliminated from the plasma and could not be detected at 120 min. In the analysis of tissue distribution, the liver was divided into three sites; the region under the diffusion cell attachment site (site 1), the treated lobe excluding site 1 (site 2), and untreated lobes (site 3). After being administered i.v., 5-FU mainly distributed in the kidney, and the concentration in the liver was significantly lower than that in kidney, spleen, or heart. After its application to the liver surface, however, 5-FU preferentially distributed at site 1, and was not detected at the other sites or in other tissues. Thus, these results suggested the possibility of a reduction in the systemic side effect of 5-FU on its application to the liver surface.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0918-6158
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1049-52
|
pubmed:meshHeading |
pubmed-meshheading:18451546-Absorption,
pubmed-meshheading:18451546-Animals,
pubmed-meshheading:18451546-Antimetabolites, Antineoplastic,
pubmed-meshheading:18451546-Diffusion Chambers, Culture,
pubmed-meshheading:18451546-Fluorouracil,
pubmed-meshheading:18451546-Injections, Intravenous,
pubmed-meshheading:18451546-Kidney,
pubmed-meshheading:18451546-Liver,
pubmed-meshheading:18451546-Male,
pubmed-meshheading:18451546-Rats,
pubmed-meshheading:18451546-Rats, Wistar,
pubmed-meshheading:18451546-Tissue Distribution
|
pubmed:year |
2008
|
pubmed:articleTitle |
Absorption and distribution characteristics of 5-fluorouracil (5-FU) after an application to the liver surface in rats in order to reduce systemic side effects.
|
pubmed:affiliation |
Department of Clinical Pharmacy, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|